Identification of CD36 molecular features required for its in vitro angiostatic activity
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Thrombospondin‐1 (TSP‐1), a natural inhibitor of angiogenesis, acts directly on endothelial cells (EC) via CD36 to inhibit their migration and morphogenesis induced by basic fibroblast growth factor. Here we show that CD36 triggered by TSP‐1 inhibits in vitro angiogenesis stimulated by vascular endothelial growth factor‐A (VEGF‐A). To demonstrate that the TSP‐1 inhibitory signal was mediated by CD36, we transduced CD36 in CD36‐deficient endothelial cells. Both TSP‐1 and the agonist anti‐CD36 mAb SMO, which mimics TSP‐1 activity, reduced the VEGF‐A 165 ‐induced migration and sprouting of CD36‐ECs. To address the mechanisms by which CD36 may exert its angiostatic function, we investigated the functional components of the C‐terminal cytoplasmic tail by site‐directed mutagenesis. Our results indicate that C464, R467, and K469 of CD36 are required for the inhibitory activity of TSP‐1. In contrast, point mutation of C466 did not alter TSP‐1 ability to inhibit EC migration and sprouting. Moreover, we show that activation of CD36 by TSP‐1 down‐modulates the VEGF receptor‐2 (VEGFR‐2) and p38 mitogen‐associated protein kinase phosphorylation induced by VEGF‐A 165 , and this effect was specifically abolished by point mutation at C464. These results identify specific amino acids of the C‐terminal cytoplasmic tail of CD36 crucial for the in vitro angiostatic activity of TSP‐1 and extend our knowledge of regulation of VEGFR‐2‐mediated biological activities on ECs.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Vascular-specific growth factors and blood vessel formation
Yancopoulos, G. D., Davis, S., Gale, N. W., Rudge, J. S., Wiegand, S. J., & Holash, J. (2000) · Nature · doi:10.1038/35025215 · Cited by 3,699
Bussolino, F., Di Renzo, M. F., Ziche, M., Bocchietto, E., Olivero, M., Naldini, L., Gaudino, G., Tamagnone, L., Coffer, A., & Comoglio, P. M. (1992) · The Journal of cell biology · doi:10.1083/jcb.119.3.629 · Cited by 1,337
Self-citationEffects of Angiogenesis Inhibitors on Multistage Carcinogenesis in Mice
Bergers, G., Javaherian, K., Lo, K.-M., Folkman, J., & Hanahan, D. (1999) · Science · doi:10.1126/science.284.5415.808 · Cited by 988
Cited by
Scavenger Receptors in Atherosclerosis: Beyond Lipid Uptake
Moore, K. J., & Freeman, M. W. (2006) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000229218.97976.43 · Cited by 562
Molecular Basis for the Regulation of Angiogenesis by Thrombospondin-1 and -2
Lawler, P. R., & Lawler, J. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006627 · Cited by 532
Adams, J. C., & Lawler, J. (2011) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a009712 · Cited by 457
Thrombospondins: from structure to therapeutics: Thrombospondins in cancer
Kazerounian, S., Yee, K. O., & Lawler, J. (2008) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7486-z · Cited by 277
DeFilippis, R. A., Chang, H., Dumont, N., Rabban, J. T., Chen, Y.-Y., Fontenay, G. V., Berman, H. K., Gauthier, M. L., Zhao, J., Hu, D., et al. (2012) · Cancer Discovery · doi:10.1158/2159-8290.cd-12-0107 · Cited by 212
Metadata
- Authors
- Primo, L., Ferrandi, C., Roca, C., Marchiò, S., Di Blasio, L., Alessio, M., & Bussolino, F.
- Venue
- The FASEB Journal
- Publisher
- Wiley
- Published
- 2005-07-21
- Volume
- 19
- Issue
- 12
- Pages
- 1713-1715
- ISSN
- 0892-6638 (ISSN-L)
- 1530-6860
- OpenAlex
- W2096384115
- Cited by
- 78
- References
- 3
- FWCI
- 2.07
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Identification of CD36 molecular features required for its in vitro angiostatic activity. https://app.cochat.ai/papers/10.1096/fj.05-3697fje
- The paper
- Primo, L., Ferrandi, C., Roca, C., Marchiò, S., Di Blasio, L., Alessio, M., & Bussolino, F. (2005). Identification of CD36 molecular features required for its in vitro angiostatic activity. The FASEB Journal. https://doi.org/10.1096/fj.05-3697fje
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.